Why the study?
Does sacubitril/valsartan improve morbidity and mortality in patients with heart failure?
Does sacubitril/valsartan improve morbidity and mortality in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Sacubitril/valsartan is highlighted as a significant innovation for improving morbidity and mortality in heart failure patients.
Heart failure (HF) is a crescent, solemn and multiple etiology worldwide health problem, which, besides potentially fatal, decreases the life quality of the affected people, mainly the elderly. Despite having obtained drugs that help in the disease development control, have been sought new alternatives for better management of these individuals. The LCZ696, a neprilysin inhibitor (sacubitril) associated with an ARB (valsartan) has shown signifiant improvements in patients' morbidity and mortality, which puts it as a good and interesting option for the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Mendes et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: